3-Amino-7-phthalazinylbenzoisoxazoles as a Novel Class of Potent, Selective, and Orally Available Inhibitors of p38α Mitogen-Activated Protein Kinase
作者:Liping H. Pettus、Shimin Xu、Guo-Qiang Cao、Partha P. Chakrabarti、Robert M. Rzasa、Kelvin Sham、Ryan P. Wurz、Dawei Zhang、Scott Middleton、Bradley Henkle、Matthew H. Plant、Christiaan J. M. Saris、Lisa Sherman、Lu Min Wong、David A. Powers、Yanyan Tudor、Violeta Yu、Matthew R. Lee、Rashid Syed、Faye Hsieh、Andrew S. Tasker
DOI:10.1021/jm8005405
日期:2008.10.23
many other diseases where aberrant cytokine signaling is the driver of disease. Herein, we describe a novel class of 3-amino-7-phthalazinylbenzoisoxazole-based inhibitors. With relatively low molecular weight, these compounds are highly potent in enzyme and cell-based assays, with minimal protein shift in 50% human whole blood. Compound 3c was efficacious (ED 50 = 0.05 mg/kg) in the rat collagen induced
p38丝裂原活化蛋白激酶(MAPK)是许多促炎途径中的中心信号分子,调节细胞对多种外界刺激的反应,包括热,紫外线,渗透压以及多种细胞因子,尤其是白介素1beta和肿瘤坏死因子α。因此,假定该酶的抑制剂具有用于治疗类风湿性关节炎,炎性肠病,骨质疏松症和许多其他异常细胞因子信号传导是疾病驱动因素的疾病的治疗潜力。在这里,我们描述了一种新型的基于3-氨基-7-酞嗪基苯并异恶唑的抑制剂。这些化合物具有相对较低的分子量,在基于酶和细胞的测定中非常有效,在50%的人类全血中蛋白质迁移最少。